Lili C. Kopala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lili C. Kopala has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Kimberley P. Good
3 shared publicationsWilliam G. Honer
3 shared publicationsW G Honer
2 shared publications- Alex MacKay
Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
1 shared publication Anne S. Bassett
1 shared publicationC Shea
1 shared publication
Latest Publications
- 31 October 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 86, S76-S77
0460 ABNORMALITIES OF SUBREGIONAL MYELINATION IN FIRST-EPISODE PSYCHOSIS PATIENTS USING MYELIN WATER IMAGING
- 31 October 2006
- Published by Elsevier in Schizophrenia Research
- Vol. 86, S76-S77
0460 ABNORMALITIES OF SUBREGIONAL MYELINATION IN FIRST-EPISODE PSYCHOSIS PATIENTS USING MYELIN WATER IMAGING
- 1 August 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (8) , 1286-1290
Impaired Olfactory Identification in Relatives of Patients With Familial Schizophrenia
OBJECTIVE: Impaired olfactory identification ability has previously been demonstrated in patients with schizophrenia. This study assessed olfactory function in psychotic and nonpsychotic members of...
- 1 August 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (8) , 1286-1290
Impaired Olfactory Identification in Relatives of Patients With Familial Schizophrenia
OBJECTIVE: Impaired olfactory identification ability has previously been demonstrated in patients with schizophrenia. This study assessed olfactory function in psychotic and nonpsychotic members of...
- 1 January 1998
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 155 (1) , 134-136
Olfactory Function in Monozygotic Twins Discordant for Schizophrenia
Abnormalities of olfactory identification ability have been proposed as a marker of cerebral dysfunction in schizophrenia. The authors studied the potential role of genetic factors in olfactory dysfunction by assessing monozygotic twins discordant for schizophrenia and matched comparison subjects. The subjects were 12 pairs of monozygotic twins discordant for schizophrenia and 12 healthy subjects matched for sex and age. Each subject completed the University of Pennsylvania Smell Identification Test. The combined twin group scored significantly lower on smell identification than did the comparison group. The affected and unaffected twin groups did not differ from each other. Genetic factors may contribute to cerebral dysfunction as assessed by olfactory identification ability.
- 1 January 1998
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 155 (1) , 134-136
Olfactory Function in Monozygotic Twins Discordant for Schizophrenia
Abnormalities of olfactory identification ability have been proposed as a marker of cerebral dysfunction in schizophrenia. The authors studied the potential role of genetic factors in olfactory dysfunction by assessing monozygotic twins discordant for schizophrenia and matched comparison subjects. The subjects were 12 pairs of monozygotic twins discordant for schizophrenia and 12 healthy subjects matched for sex and age. Each subject completed the University of Pennsylvania Smell Identification Test. The combined twin group scored significantly lower on smell identification than did the comparison group. The affected and unaffected twin groups did not differ from each other. Genetic factors may contribute to cerebral dysfunction as assessed by olfactory identification ability.
- 1 August 1997
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 17 (4) , 308-313
Extrapyramidal Signs and Clinical Symptoms in First-Episode Schizophrenia
The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone. Twenty-two (17 men; 5 women) patients were examined using the Extrapyramidal Symptom Rating Scale, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity of Illness and Improvement, and Global Assessment of Functioning. Three patients (14%) had distinct EPS at baseline, whereas all were free of EPS after treatment with risperidone. On the maximum dose of risperidone (5-8 mg), 32% of the total sample developed mild akathisia or parkinsonism, both of which diminished with dosage reduction. No clinically significant EPS were observed in patients receiving 2 to 4 mg of risperidone. Analysis of symptom response of the lower (2-4 mg) versus the higher (5-8 mg) doses of risperidone resulted in superior outcome in the 2- to 4-mg group for all three symptom clusters of the PANSS. In addition, 91% of the low-dose group achieved a 20% or greater reduction in total PANSS score compared with 27% for the high-dose group. These findings have clinical relevance directed at the early and longer-term treatment of schizophrenia.
- 1 August 1997
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 17 (4) , 308-313
Extrapyramidal Signs and Clinical Symptoms in First-Episode Schizophrenia
The purpose of this study was to determine the prevalence of extrapyramidal signs or symptoms (EPS) and clinical symptoms in first-episode schizophrenia, before any treatment, during and after treatment with a novel antipsychotic, risperidone. Twenty-two (17 men; 5 women) patients were examined using the Extrapyramidal Symptom Rating Scale, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity of Illness and Improvement, and Global Assessment of Functioning. Three patients (14%) had distinct EPS at baseline, whereas all were free of EPS after treatment with risperidone. On the maximum dose of risperidone (5-8 mg), 32% of the total sample developed mild akathisia or parkinsonism, both of which diminished with dosage reduction. No clinically significant EPS were observed in patients receiving 2 to 4 mg of risperidone. Analysis of symptom response of the lower (2-4 mg) versus the higher (5-8 mg) doses of risperidone resulted in superior outcome in the 2- to 4-mg group for all three symptom clusters of the PANSS. In addition, 91% of the low-dose group achieved a 20% or greater reduction in total PANSS score compared with 27% for the high-dose group. These findings have clinical relevance directed at the early and longer-term treatment of schizophrenia.
- 1 January 1997
- Vol. 22 (1) , 56-60
Clinical features of schizophrenia in a woman with hyperandrogenism.
Ample evidence supports sex differences in the clinical features of schizophrenia. In this regard, estrogen may contribute to later onset and less severe course of illness in women. Direct investigation of hormonal status in schizophrenia is extremely difficult. The present report documents the clinical features of schizophrenia in a young woman with long-standing hyperandrogenism related to polycystic ovarian disease. We postulate that hyperandrogenism contributed to a relatively early onset, olfactory dysfunction, and other clinical features of schizophrenia more commonly associated with men. Additionally, acute estrogen depletion following cessation of oral contraceptives may have precipitated psychosis, while recommencement of oral contraceptives could have contributed to subsequent improvement in symptoms.
- 1 January 1997
- Vol. 22 (1) , 56-60
Clinical features of schizophrenia in a woman with hyperandrogenism.
Ample evidence supports sex differences in the clinical features of schizophrenia. In this regard, estrogen may contribute to later onset and less severe course of illness in women. Direct investigation of hormonal status in schizophrenia is extremely difficult. The present report documents the clinical features of schizophrenia in a young woman with long-standing hyperandrogenism related to polycystic ovarian disease. We postulate that hyperandrogenism contributed to a relatively early onset, olfactory dysfunction, and other clinical features of schizophrenia more commonly associated with men. Additionally, acute estrogen depletion following cessation of oral contraceptives may have precipitated psychosis, while recommencement of oral contraceptives could have contributed to subsequent improvement in symptoms.